虚拟现实导航用于早期发现阿尔茨海默病
Sayuri Shima1, Reiko Ohdake1, Yasuaki Mizutani1
1Department of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Frontiers in aging neuroscience
|September 5, 2025
概括
通过3D虚拟现实导航测量的路径集成 (PI) 错误与阿尔茨海默病 (AD) 生物标志物相关. 血p-tau181是关键预测因素,表明PI是早期发现AD的非侵入性工具.
科学领域:
- 神经科学
- 生物标志物发现
- 诊断技术
背景情况:
- 早期发现阿尔茨海默病 (AD) 对于及时干预至关重要.
- 在AD中神经纤维纠会影响脑内皮层,影响空间导航.
- 路径整合 (PI) 是一种由脑内皮层介导的认知功能.
研究的目的:
- 调查路径整合 (PI) 作为早期阿尔茨海默病 (AD) 检测的非侵入性替代标志物.
- 探索PI错误与AD相关的血生物标志物之间的相关性.
- 评估3D虚拟现实 (VR) 导航系统在诊断目的的PI量化中的实用性.
主要方法:
- 111名健康成年人接受了3D虚拟现实导航以评估PI.
- 收集的血生物标志物 (GFAP,NfL,Aβ40,Aβ42,p-tau181) 和ApoE基因型.
- 统计分析包括多变量线性回归,逻辑回归和机器学习的预测重要性.
主要成果:
- 在PI误差,年龄和血GFAP,p- tau181和NfL水平之间发现了显著的正相关性.
- 在多变量分析中,血GFAP和p-tau181与PI误差有显著的相关性.
- 机器学习发现血p-tau181是PI错误的最重要的预测因子.
结论:
- 用3D虚拟现实量化的PI显示了早期AD病理生理学的替代诊断工具的潜力.
- 3D VR PI和血p-tau181的组合可以作为早期AD神经退行症的有效生物标志物.
- 这些发现支持开发用于早期发现和监测AD的非侵入性工具,从而促进及时的治疗干预.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


